USD10
ABVX Shares
About AbivaxAbivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
USD10
ABVX Shares
About AbivaxAbivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 24 at 1:30 PM GMT+0
MARKET CAP
$9.26B
OPEN PRICE
Not enough data
LOW (1Y)
$4.77
HIGH (1Y)
$148.83
LOW (24H)
$115.75
HIGH (24H)
$125.48
VOLUME (24H)
$58.00
100%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $116.50 | |
1 Week | $123.91 | |
1 Month | $132.20 | |
1 Year | $7.34 |